Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.40 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460710 | 1.00 | CXCR2 (0.40) | CXCR2KCNK2PDE2ACHRM2CNR1 | |
| SCHEMBL25189696 | 0.91 | CXCR2 (0.43) | CXCR2KCNK2PDE2A | |
| SCHEMBL25189697 | 0.91 | CXCR2 (0.43) | CXCR2KCNK2PDE2A | |
| SCHEMBL38666109 | 0.86 | CXCR2 (0.43) | CXCR2KCNK2PDE2A | |
| SCHEMBL23460924 | 0.86 | CXCR2 (0.43) | CXCR2KCNK2PDE2A | |
| SCHEMBL23460926 | 0.86 | CXCR2 (0.43) | CXCR2KCNK2PDE2A | |
| SCHEMBL25555880 | 0.85 | CXCR2 (0.40) | CXCR2KCNK2PDE2ACHRM2CNR1 | |
| SCHEMBL25549146 | 0.85 | CXCR2 (0.40) | CXCR2KCNK2PDE2ACHRM2CNR1 | |
| SCHEMBL23461209 | 0.85 | CXCR2 (0.42) | CXCR2KCNK2PDE2A | |
| SCHEMBL23461207 | 0.85 | CXCR2 (0.42) | CXCR2KCNK2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113806-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885KCNK2 1269/4885PDE2A 356/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | CXCR2 63/4885KCNK2 395/4885PDE2A 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.